WordNet

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 難治性および再発性の小細胞肺癌の治療 treatment of refractory and relapsed small cell lung cancer
2. 抗腫瘍療法関連肺毒性：細胞傷害性薬物 pulmonary toxicity associated with antineoplastic therapy cytotoxic agents
3. 進展型小細胞肺癌：初期マネージメント extensive stage small cell lung cancer initial management
4. 肺外原発小細胞癌 extrapulmonary small cell cancer
5. 過敏性腸症候群に対するアロセトロン塩酸塩（Lotronex） alosetron hydrochloride lotronex for irritable bowel syndrome

Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.

Galsky MD1, Hahn NM2, Wong B3, Lee KM4, Argiriadi P4, Albany C5, Gimpel-Tetra K4, Lowe N4, Shahin M4, Patel V4, Tsao CK4, Oh WK4.
Cancer chemotherapy and pharmacology.Cancer Chemother Pharmacol.2015 Oct 13. [Epub ahead of print]
PURPOSE: The purpose of this investigator-initiated multicenter phase II study was to determine the activity of the third-generation synthetic anthracycline, amrubicin, administered as second-line therapy in patients with advanced urothelial carcinoma.METHODS: Patients with progressive metastatic ur
PMID 26464352

Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.

Asao T1, Nokihara H1, Yoh K2, Niho S2, Goto K2, Ohmatsu H2, Kubota K3, Yamamoto N1, Sekine I4, Kunitoh H5, Fujiwara Y6, Ohe Y1.
Japanese journal of clinical oncology.Jpn J Clin Oncol.2015 Oct;45(10):941-6. doi: 10.1093/jjco/hyv107. Epub 2015 Jul 31.
OBJECTIVE: Most of the previous studies of amrubicin in patients with previously treated small-cell lung cancer were conducted at a dose of 40 mg/m(2). The aim of this study was to assess the efficacy and safety of amrubicin at a dose of 45 mg/m(2) in patients with relapsed or refractory small-cell
PMID 26232449

Lactate dehydrogenase and body mass index are prognostic factors in patients with recurrent small cell lung cancer receiving amrubicin.

Inomata M1, Hayashi R1, Tokui K1, Taka C1, Okazawa S1, Kambara K1, Ichikawa T1, Yamada T1, Miwa T1, Kashii T2, Matsui S1, Tobe K1.
Tumori.Tumori.2015 Sep 30;0(0):0. doi: 10.5301/tj.5000435. [Epub ahead of print]
AIMS AND BACKGROUND: Amrubicin monotherapy can be an effective treatment option for patients with recurrent small cell lung cancer (SCLC). We conducted this retrospective study to investigate the prognostic factors in patients with recurrent SCLC receiving amrubicin monotherapy.METHODS: The associat
PMID 26429641

Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer

Ogawara Daiki,Fukuda Minoru,Nakamura Yoichi,Kohno Shigeru
Cancer Management and Research 2(1), 191-195, 2010-08
… Recent clinical studies have demonstrated the promising efficacy of amrubicin for patients with relapsed SCLC. … This review presents the results of clinical studies showing the efficacy and safety of amrubicin for the treatment of relapsed SCLC. … Amrubicin is a synthetic anthracycline agent with a similar structure to doxorubicin, in which the hydroxyl group at position 9 in amrubicin is replaced by an amino group to enhance efficacy. …
NAID 120002513789